Athira Pharma Q1 2025 Earnings Report

Athira Pharma EPS Results

• Actual EPS: -$0.23
• Consensus EPS: -$0.20
• Beat/Miss: Missed by -$0.03
• One Year Ago EPS: N/A

Athira Pharma Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Athira Pharma Announcement Details

• Quarter: Q1 2025
• Date: 5/9/2025
• Time: Before Market Opens
• Conference Call Date: Friday, May 9, 2025
• Conference Call Time: 4:00PM ET

Athira Pharma (NASDAQ:ATHA) is a clinical‐stage biopharmaceutical company focused on developing innovative therapies aimed at restoring neuronal health and function in patients with neurodegenerative disorders. The company’s lead product candidate, fosgonimeton (ATH‐701), is designed as a positive modulator of the HGF/MET neurotrophic system to support synaptic repair and cognitive function. Athira Pharma’s research and development efforts target a range of central nervous system conditions, including mild cognitive impairment due to Alzheimer’s disease and other neurodegenerative indications with high unmet medical need.

Founded in 2011 and headquartered in Bothell, Washington, Athira Pharma has built a pipeline leveraging small‐molecule biology to promote neuroregeneration and address the underlying causes of neuronal decline. The company has advanced its lead candidate through Phase 2 clinical trials and continues to explore additional compounds in preclinical stages that may further broaden its therapeutic reach. Athira’s R&D operations encompass discovery, preclinical testing and clinical development, supported by collaborations with academic institutions and contract research organizations across North America and Europe.

In June 2019, Athira Pharma completed a business combination with a special purpose acquisition company, gaining a public listing on the Nasdaq market under the ticker ATHA. This strategic move has enabled the company to accelerate its development programs and expand its clinical trial footprint. Athira maintains its principal laboratory and operational facilities in the Pacific Northwest while coordinating global investigator sites to evaluate safety and efficacy across diverse patient populations.

Leadership at Athira Pharma is spearheaded by co‐founder and Chief Executive Officer Dr. Leen Kawas, whose expertise in neuroscience drug discovery has guided the company since inception. The executive team and board of directors bring a wealth of experience in biopharmaceutical development, regulatory affairs and commercial strategy, positioning Athira to address the complexities of neurodegenerative disease treatment. As the company advances its pipeline, it remains committed to scientific rigor and patient‐centric innovation in the quest to restore cognitive health.